Stephen Samuel Opat (Stephen S Opat, Stephen Opat)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 27

Top Venues

Blood advances

Leukemia & lymphoma

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Blood cancer journal

Monash Health

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Monash Health

Australia

Director, Clinical Haematology :: Clinical Haematology

Publications

Constantine S Tam, Judith Trotman, Stephen Samuel Opat, Jennifer C Stern, Heather Allewelt, Kunthel By, William Novotny, Jane Huang, Alessandra Tedeschi
Zanubrutinib in patients with relapsed/refractory hairy cell leukemia. Blood advances (2023)
Constantine S Tam, Javier L Muñoz, John Francis Seymour, Stephen Samuel Opat
Correction: Zanubrutinib: past, present, and future. Blood cancer journal 13 (1) (2023)
Amanda Tey, James Schwarer, Robert Raffa, Emily Shi, Eldho Paul, Stephen Samuel Opat, Claire Dendle, Jake Shortt
High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma. European journal of haematology (2023)
Meletios- Athanasios Dimopoulos, Stephen Samuel Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn Engelbrekt Wahlin, Miriam Santero, Helen McCarthy, Stephen P Mulligan, Alessandra Tedeschi, Jorge J Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C Minnema, Christian Buske, Veronique Leblond, Steven P Treon, Judith Trotman, Wai Y Chan, Jingjing Schneider, Heather Allewelt, Sheel Patel, Aileen Cohen, Constantine S Tam
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Yuqin Song, Ke-Shu Zhou, Dehui Zou, Dengju Li, Jian-da Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Dao-Bin Zhou, Constantine S Tam, David Simpson, Michael L Wang, Tycel J Phillips, Stephen Samuel Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer medicine (2023)
Maciej Tatarczuch, Mark Waltham, Jake Shortt, Galina Polekhina, Eliza A Hawkes, Shir-Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica Li, Vanitha Ramakrishnan, Karin Dunne, Stephen Samuel Opat, Gareth Peter Gregory
Molecular associations of response to the new generation BTK inhibitor zanubrutinib in marginal zone lymphoma. Blood advances (2023)
Constantine S Tam, Javier L Muñoz, John Francis Seymour, Stephen Samuel Opat
Zanubrutinib: past, present, and future. Blood cancer journal 13 (1) (2023)
Meletios- Athanasios Dimopoulos, Stephen Samuel Opat, Steven P Treon, Constantine S Tam
Reply to Y. Song et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Stephen Samuel Opat, Alessandra Tedeschi, Bei Hu, Kim M Linton, Pamela McKay, Sophie Leitch, Morton Coleman, Pier Luigi Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter J Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit M Ardeshna, Fontanet Bijou, Patricia A Walker, Eliza A Hawkes, Shir Jing Ho, Ke-Shu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood advances (2023)
Michael K Odutola, Marina T van Leeuwen, Fiona Jane Bruinsma, Jennifer Turner, Mark Hertzberg, John Francis Seymour, Henry Miles Prince, Judith Trotman, Emma Verner, Fernando Roncolato, Stephen Samuel Opat, Robert Lindeman, Campbell Tiley, Samuel T Milliken, Underhill Craig, Geza Benke, Graham G Giles, Claire M Vajdic
A population-based family case-control study of sun exposure and follicular lymphoma risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
Ross Thomas Salvaris, Stephen P Mulligan, Andrea Puig, Marija McGeachie, Stephen Samuel Opat
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia. Internal medicine journal (2023)
Michael K Odutola, Marina T van Leeuwen, Jennifer Turner, Fiona Jane Bruinsma, John Francis Seymour, Henry Miles Prince, Samuel T Milliken, Judith Trotman, Emma Verner, Campbell Tiley, Fernando Roncolato, Craig R Underhill, Stephen Samuel Opat, Michael Harvey, Mark Hertzberg, Geza Benke, Graham G Giles, Claire M Vajdic
Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. Cancers 14 (11) (2022)
Jemima H Miller, Michael Gilbertson, Michael P MacManus, Andrew Wirth, Stephen Samuel Opat, Gareth Peter Gregory
Salvage radiotherapy is associated with durable response for a subset of patients with limited-stage refractory DLBCL. Blood advances 5 (23) (2022)
Tycel Phillips, Henry S H Chan, Constantine S Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Samuel Opat, Hyeon Seok Eom, Heather Allewelt, Jennifer C Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood advances 6 (11) (2022)
Stephen Samuel Opat
Targeted Therapy in Leukaemia, Lymphoma and Myeloma. Journal of personalized medicine 12 (1) (2022)
Bilal Tariq, Ying C Ou, Jennifer C Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman, Stephen Samuel Opat
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & lymphoma (2022)
Alex F Herrera, Samuel Tracy, Brandon Croft, Stephen Samuel Opat, Jill Ray, Alex F Lovejoy, Lisa Musick, Joseph N Paulson, Laurie Helen Sehn, Yanwen Jiang
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood advances 6 (6) (2022)
Jonathan Wong, Emily Gruber, Belinda Maher, Mark Waltham, Zahra Sabouri-Thompson, Ian Jong, Quinton Luong, Sidney Levy, Beena Kumar, Daniella Brasacchio, Wendy Jia, Joan So, Hugh Skinner, Alexander Lewis, Simon J Hogg, Stephin Vervoort, Carmen DiCorleto, Micheleine Uhe, Jeanette Gamgee, Stephen Samuel Opat, Gareth P Gregory, Galina Polekhina, John Reynolds, Eliza A Hawkes, Gajan Kailainathan, Robin Gasiorowski, Lev M Kats, Jake Shortt
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia 36 (6) (2022)
Stephen P Mulligan, Stephen Samuel Opat, Chan Yoon Y Cheah, Bryone Kuss, Mark Hertzberg, Paula Marlton, Sarah Poplar, Andrea Puig, Marija McGeachie, Robert Weinkove, Constantine S Tam
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program. Leukemia & lymphoma (2022)
Stephen P Mulligan, Stephen Samuel Opat, Paula Marlton, Bryone J Kuss, Poppy Gerungan, Andrea Puig, Marija McGeachie, Constantine S Tam
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. British journal of haematology 198 (4) (2022)
William G Wierda, John N Allan, Tanya Siddiqi, Thomas J Kipps, Stephen Samuel Opat, Alessandra Tedeschi, Xavier C Badoux, Bryone J Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M Pagel, Ian W Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer-Glusman, Joi Ninomoto, James P Dean, Danelle F James, Paolo Ghia, Constantine S Tam
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (34) (2021)
Stephen Samuel Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A Portell, Kirit M Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (23) (2021)
Laurie H Sehn, Mark Hertzberg, Stephen Samuel Opat, Alex F Herrera, Sarit Assouline, Christopher R Flowers, Tae Min Kim, Andrew K McMillan, Muhit Özcan, Violaine Safar, Gilles Andre Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J Matasar
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort. Blood advances (2021)
Jonathan Wing Kit Wong, Meaghan Wall, Gregory Philip Corboy, Nadine Taubenheim, Gareth Peter Gregory, Stephen Samuel Opat, Jake Shortt
Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Cold Spring Harbor molecular case studies 6 (4) (2020)
Maciej Tatarczuch, Erin Paul, Michael Gilberston, Gareth Peter Gregory, Constantine S Tam, Hang Quach, Ali Bazargan, Robin Filshie, Matthew Ku, Amanda Tey, Jake Shortt, Stephen Samuel Opat
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia & lymphoma 62 (1) (2020)
Ross Thomas Salvaris, Stephen Samuel Opat
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. Future oncology (London, England) 17 (4) (2020)
Sumita Ratnasingam, Joshua Casan, Jake Shortt, Eliza Hawkes, Michael Gilbertson, Zoe McQuilten, George Grigoriadis, Kay Thwe Htun, Swe Myo Htet, Philip Campbell, Khai Li Chai, Hang Quach, Sushrut Patil, Stephen Samuel Opat
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Scientific reports 9 (1) (2019)

Stephen Samuel Opat.css-eqlu8i{font-size:small;padding-left:4px;} (Stephen S Opat, Stephen Opat)

Publication Activity (10 Years)

Top Topics

Top Venues

Stephen Samuel Opat (Stephen S Opat, Stephen Opat)